Promising Outlook for AN2 Therapeutics: Buy Rating Backed by Strong Phase 2 Results and Anticipated FDA Discussions
Roy Buchanan, an analyst from JMP Securities, reiterated the Buy rating on AN2 Therapeutics, Inc. (ANTX – Research Report). The associated ...
Promising Potential of Epetraborole in Treating MAC Lung Disease Drives Buy Rating for AN2 Therapeutics
In a report released today, Roy Buchanan from JMP Securities maintained a Buy rating on AN2 Therapeutics, Inc. (ANTX – Research Report), with a ...
JMP Securities maintains AN2 Therapeutics stock with $5 target
JMP Securities reiterated its Market Outperform rating on AN2 Therapeutics (NASDAQ:ANTX) shares, maintaining a $5.00 price target, representing significant upside from the current price of $1.14.